Etomay, Rosenda G.

HRN: 16-24-09  Sex: Female

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2023
CLINDAMYCIN 150MG/ML, 4ML (AMP)
11/30/2023
12/28/2023
IV
600mg
Q8
DM Foot
Waiting Final Action 
11/30/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
11/30/2023
12/07/2023
IV
1.5
Q6
DM Foot
Waiting Final Action 
12/03/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
12/03/2023
12/10/2023
IV
4.5g As LD Then 2.25g
Q8
Infected Diabetic Foot, Right
Waiting Final Action 
12/10/2023
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
12/10/2023
12/16/2023
IV
2.25gm
Q6
Infected Diabetic Foot Right
Waiting Final Action 
12/14/2023
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
12/14/2023
12/21/2023
TOPICAL
1%
OD
Infected Wound
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

 Indication:

              

 Type of Infection:

                             

           

 Compliance to guidelines:



 Initial appropriateness:



 If inappropriate:

           

 Final appropriateness:



 If inappropriate:

              

 Overall appropriateness: